FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3034691659> ?p ?o ?g. }

• W3034691659 endingPage "589.e5" @default.
• W3034691659 startingPage "580" @default.
• W3034691659 abstract "Background & AimsThe profile of chronic liver disease (CLD) in the United States has changed due to obesity trends and advances in treatment of viral hepatitis. We assessed liver transplant listing trends by CLD etiology.MethodsAdult candidates for liver transplantation were selected from the Scientific Registry of Transplant Recipients (2002 through 2019). We calculated proportion trends for common CLD etiologies at time of placement on the wait list, including chronic infection with hepatitis B virus, chronic infection with hepatitis C virus (HCV), nonalcoholic steatohepatitis (NASH, including cryptogenic cirrhosis), alcohol-related liver disease (ALD) without or with chronic HCV infection, autoimmune hepatitis, primary biliary cholangitis, and primary sclerosing cholangitis, in patients with and without hepatocellular carcinoma (HCC).ResultsFrom the 168,441 patients with known etiology and non-acute liver failure on the liver transplant waitlist, 27,799 patients (16.5%) had HCC. In 2002, the most common etiologies in patients without HCC were chronic HCV infection (37%) and ALD (16%), whereas only 5% had NASH. Among patients with HCC, 58% had chronic HCV infection and 10% had ALD and only 1% had NASH. In 2019, among patients without HCC, NASH was the second leading indication for liver transplantation (28% of patients), after ALD (38% of patients). Among patients with HCC, chronic HCV infection remained the leading indication (40% of patients) but NASH (24% of patients) surpassed ALD (16% of patients) to become the second leading indication. NASH was the leading indication in women without HCC (34%), in patients older than 54 years (36%), and in patients on Medicare (41%). In trend analysis, NASH was the most rapidly increasing indication for liver transplantation in patients without HCC (Kendall tau=0.97; P < .001) and in patients with HCC (tau=0.94; P < .0001).ConclusionsIn an analysis of data from the Scientific Registry of Transplant Recipients (2002 through 2019), we found NASH to be the second most common indication for liver transplant in 2019, and the fastest increasing indication. In 2019, NASH was the leading indication for liver transplantation among women without HCC. The profile of chronic liver disease (CLD) in the United States has changed due to obesity trends and advances in treatment of viral hepatitis. We assessed liver transplant listing trends by CLD etiology. Adult candidates for liver transplantation were selected from the Scientific Registry of Transplant Recipients (2002 through 2019). We calculated proportion trends for common CLD etiologies at time of placement on the wait list, including chronic infection with hepatitis B virus, chronic infection with hepatitis C virus (HCV), nonalcoholic steatohepatitis (NASH, including cryptogenic cirrhosis), alcohol-related liver disease (ALD) without or with chronic HCV infection, autoimmune hepatitis, primary biliary cholangitis, and primary sclerosing cholangitis, in patients with and without hepatocellular carcinoma (HCC). From the 168,441 patients with known etiology and non-acute liver failure on the liver transplant waitlist, 27,799 patients (16.5%) had HCC. In 2002, the most common etiologies in patients without HCC were chronic HCV infection (37%) and ALD (16%), whereas only 5% had NASH. Among patients with HCC, 58% had chronic HCV infection and 10% had ALD and only 1% had NASH. In 2019, among patients without HCC, NASH was the second leading indication for liver transplantation (28% of patients), after ALD (38% of patients). Among patients with HCC, chronic HCV infection remained the leading indication (40% of patients) but NASH (24% of patients) surpassed ALD (16% of patients) to become the second leading indication. NASH was the leading indication in women without HCC (34%), in patients older than 54 years (36%), and in patients on Medicare (41%). In trend analysis, NASH was the most rapidly increasing indication for liver transplantation in patients without HCC (Kendall tau=0.97; P < .001) and in patients with HCC (tau=0.94; P < .0001). In an analysis of data from the Scientific Registry of Transplant Recipients (2002 through 2019), we found NASH to be the second most common indication for liver transplant in 2019, and the fastest increasing indication. In 2019, NASH was the leading indication for liver transplantation among women without HCC." @default.
• W3034691659 created "2020-06-19" @default.
• W3034691659 creator A5000313377 @default.
• W3034691659 creator A5002917529 @default.
• W3034691659 creator A5010138815 @default.
• W3034691659 creator A5019233824 @default.
• W3034691659 creator A5069923152 @default.
• W3034691659 creator A5071309777 @default.
• W3034691659 creator A5074202766 @default.
• W3034691659 creator A5079801760 @default.
• W3034691659 creator A5080386622 @default.
• W3034691659 date "2021-03-01" @default.
• W3034691659 modified "2023-10-14" @default.
• W3034691659 title "Nonalcoholic Steatohepatitis Is the Most Rapidly Increasing Indication for Liver Transplantation in the United States" @default.
• W3034691659 cites W1434570074 @default.
• W3034691659 cites W2015802619 @default.
• W3034691659 cites W2039720377 @default.
• W3034691659 cites W2048613643 @default.
• W3034691659 cites W2059630954 @default.
• W3034691659 cites W2062774204 @default.
• W3034691659 cites W2076341209 @default.
• W3034691659 cites W2078630806 @default.
• W3034691659 cites W2264072217 @default.
• W3034691659 cites W2582878252 @default.
• W3034691659 cites W2592678743 @default.
• W3034691659 cites W2599153295 @default.
• W3034691659 cites W2615006629 @default.
• W3034691659 cites W2738249467 @default.
• W3034691659 cites W2738659466 @default.
• W3034691659 cites W2744982526 @default.
• W3034691659 cites W2760044546 @default.
• W3034691659 cites W2795440260 @default.
• W3034691659 cites W2799714806 @default.
• W3034691659 cites W2805977157 @default.
• W3034691659 cites W2808368206 @default.
• W3034691659 cites W2886217120 @default.
• W3034691659 cites W2886906900 @default.
• W3034691659 cites W2891744413 @default.
• W3034691659 cites W2891971495 @default.
• W3034691659 cites W2896193828 @default.
• W3034691659 cites W2903133800 @default.
• W3034691659 cites W2911713072 @default.
• W3034691659 cites W2914412536 @default.
• W3034691659 cites W2922213148 @default.
• W3034691659 cites W2924630617 @default.
• W3034691659 cites W2940072191 @default.
• W3034691659 cites W2941977933 @default.
• W3034691659 cites W2955615964 @default.
• W3034691659 cites W2966059605 @default.
• W3034691659 cites W2968982492 @default.
• W3034691659 cites W2990737007 @default.
• W3034691659 cites W3006500690 @default.
• W3034691659 cites W4232620598 @default.
• W3034691659 doi "https://doi.org/10.1016/j.cgh.2020.05.064" @default.
• W3034691659 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32531342" @default.
• W3034691659 hasPublicationYear "2021" @default.
• W3034691659 type Work @default.
• W3034691659 sameAs 3034691659 @default.
• W3034691659 citedByCount "227" @default.
• W3034691659 countsByYear W30346916592020 @default.
• W3034691659 countsByYear W30346916592021 @default.
• W3034691659 countsByYear W30346916592022 @default.
• W3034691659 countsByYear W30346916592023 @default.
• W3034691659 crossrefType "journal-article" @default.
• W3034691659 hasAuthorship W3034691659A5000313377 @default.
• W3034691659 hasAuthorship W3034691659A5002917529 @default.
• W3034691659 hasAuthorship W3034691659A5010138815 @default.
• W3034691659 hasAuthorship W3034691659A5019233824 @default.
• W3034691659 hasAuthorship W3034691659A5069923152 @default.
• W3034691659 hasAuthorship W3034691659A5071309777 @default.
• W3034691659 hasAuthorship W3034691659A5074202766 @default.
• W3034691659 hasAuthorship W3034691659A5079801760 @default.
• W3034691659 hasAuthorship W3034691659A5080386622 @default.
• W3034691659 hasBestOaLocation W30346916591 @default.
• W3034691659 hasConcept C126322002 @default.
• W3034691659 hasConcept C137627325 @default.
• W3034691659 hasConcept C203014093 @default.
• W3034691659 hasConcept C2522874641 @default.
• W3034691659 hasConcept C2776408679 @default.
• W3034691659 hasConcept C2776455275 @default.
• W3034691659 hasConcept C2777075537 @default.
• W3034691659 hasConcept C2777214474 @default.
• W3034691659 hasConcept C2777575235 @default.
• W3034691659 hasConcept C2778019345 @default.
• W3034691659 hasConcept C2778772119 @default.
• W3034691659 hasConcept C2779102576 @default.
• W3034691659 hasConcept C2779134260 @default.
• W3034691659 hasConcept C2779478299 @default.
• W3034691659 hasConcept C2779609443 @default.
• W3034691659 hasConcept C2780366471 @default.
• W3034691659 hasConcept C2780615123 @default.
• W3034691659 hasConcept C2911091166 @default.
• W3034691659 hasConcept C71924100 @default.
• W3034691659 hasConcept C90924648 @default.
• W3034691659 hasConceptScore W3034691659C126322002 @default.
• W3034691659 hasConceptScore W3034691659C137627325 @default.
• W3034691659 hasConceptScore W3034691659C203014093 @default.
• W3034691659 hasConceptScore W3034691659C2522874641 @default.

• next